Nine of 56 (20% actuarial) patients receiving a T celldepleted, HLA-identical sibling BMT for hematological malignancy developed hemorrhagic cystitis (HC) 15-368 days post BMT. Hematuria was severe and prolonged (median duration 18 days). In eight patients (89%), a viral etiology was confirmed (four adenovirus, four polyomavirus). HC was associated with significant morbidity, with all patients requiring continuous bladder irrigation and transfusion support for blood loss and thrombocytopenia. HC occurring before day 100 was significantly associated with a reduction in longterm survival: 1/7 (14.3%) patients developing HC before day 100 became long-term survivors vs 21/49 (42.8%) without HC by day 100 (P = 0.034). In univariate analysis, HC was associated with a diagnosis of multiple myeloma (P = 0.02). There was a trend towards a higher incidence of HC in patients reactivating cytomegalovirus (CMV) compared with those remaining CMV negative (18.4 vs 5.5% respectively, P = 0.17). HC was not associated with graft-versus-host disease, or with the transplant dose of CD34 + progenitors or CD3 + cells, patient age or sex. Life-threatening, viral-induced HC and the unusually high incidence of adenovirus-induced HC may have been caused by immune deficiency associated with T cell depletion in this series.
HC. [2] [3] [4] In contrast, late HC (occurring beyond 72 h from the preparative regimen) remains a continuing complication of allogeneic BMT and appears to be virally mediated. 4 Incidence and severity of viral HC may vary according to the degree of immunosuppression associated with different techniques of graft-versus-host disease (GVHD) prevention. We previously reported that T cell depletion of donor marrow may predispose to early cytomegalovirus (CMV) reactivation and CMV-associated interstitial pneumonitis (IP) in adults with hematological malignancies. 5 In order to determine whether other virally induced complications occurred in T cell-depleted BMT recipients, we studied late HC to determine its etiology and to identify predisposing factors.
Patients and methods

Patients
Between September 1993 and January 1997, 56 patients with hematological malignancies received a T lymphocytedepleted BMT from an HLA-identical sibling. Patients were treated under National Institutes of Health protocols testing T cell-depleted BMT followed by delayed lymphocyte add-back: 93-H-0212 (chronic myelogenous leukemia), 94-H-0092 (acute myelogenous leukemia and myelodysplastic syndrome) and 94-H-0182 (multiple myeloma), approved by the local Institutional Review Board. Ages ranged from 12 to 58 years. Thirty-one patients had chronic myelogenous leukemia (CML), 23 in chronic phase, three in accelerated phase, and five in blastic transformation. Fifteen had other high-risk myeloid malignancies: eight myelodysplastic syndrome (MDS) including one with underlying Fanconi anemia, and six AML, including one eosinophilic leukemia. One patient had acute lymphocytic leukemia (ALL) in second remission at the time of BMT. Ten had multiple myeloma (MM).
Bone marrow transplantation procedure
Preparative regimen: Fifty-five patients received a preparative regimen consisting of cyclophosphamide 60 mg/kg/day i.v. for 2 consecutive days followed by 1360 cGy total body irradiation (TBI) in eight fractions over 4 days in 50 patients; 1200 cGy in six fractions over 3 days in four patients, and busulfan 16 mg/kg in one patient previously autografted using TBI. One patient with MDS evolving from Fanconi anemia received a reduced cyclophosphamide dose of 10 mg/kg/daily days Ϫ7 and Ϫ6, followed by three fractions of TBI totaling 450 cGy days Ϫ5 to Ϫ3 and fludarabine 25 mg/m 2 /day days Ϫ5 to Ϫ2. All patients received i.v. hydration with normal saline (2.5 ml/kg/h) starting 12 h before cyclophosphamide and continuing until at least 24 h after the final cyclophosphamide dose. Intravenous frusemide was used as needed to maintain the urine output of at least 1.5-2 ml/kg/h. In addition, i.v. mesna was given (50 mg/kg/day for 2 consecutive days) in three divided doses, 20 mg/kg i.v. over 1 h before cyclophosphamide, followed by 20 mg/kg i.v. over 8 h immediately following cyclophosphamide, followed by a third and final infusion of mesna at 10 mg/kg i.v. over 8 h.
Bone marrow transplantation:
A total of 1.5-2 l of marrow was harvested from the posterior iliac crests of donors under general anesthesia. In patients UPN 1-44 T cell depletion was accomplished by centrifugal counter-flow elutriation. 6 The T cell dose in the graft ranged from 0.3 to 5.7 (median 2.3) × 10 5 CD3 + cells/kg in eight patients. One patient received a T cell replete marrow because of an inadequate CD34
+ content of the depleted marrow. UPN 45-56 received marrow from G-CSF-stimulated donors. The bone marrow was processed to deplete T cells using a CD34
+ cell selection system (Ceprate SC; CellPro, Bothell, WA, USA). 7 GVHD prophylaxis and T cell add-back: Patients received cyclosporine (CsA) 3 mg/kg i.v., starting on day Ϫ4 until an oral dose CsA could be tolerated. Doses were adjusted to maintain a cyclosporine whole blood level between 200 and 400 ng/ml. CsA was continued to at least day 180 post BMT, and longer if chronic GVHD developed. To reconstitute immune function and conserve a graft-versus-leukemia effect, donor mononuclear cells obtained by leukapheresis were infused in three schedules: UPN Post-transplant infection prophylaxis: All patients received fluconazole and norfloxacin until day 30 for antifungal and antimicrobial prophylaxis, followed by bactrim weekly from days 30 to 180 as prophylaxis against pneumocystis infection. As CMV prophylaxis all patients received i.v. immunoglobulin 0.5 g/kg weekly until day 100 post BMT. Due to a high incidence of CMV reactivation and CMV pneumonitis associated with T cell depletion, 5 all patients after May 1995 (UPN 24-60) received high-dose acyclovir 8 as prophylaxis against CMV and herpes simplex virus reactivation. CMV seropositive recipients of marrow from either positive or negative donors received acyclovir 500 mg/m 2 i.v. every 8 h from day Ϫ5 until able to tolerate oral acyclovir 800 mg every 6 h until day 100. For CMV negative recipients of marrow from seronegative donors, acyclovir 200 mg p.o. every 8 h was given from day Ϫ5 to day 100 or acyclovir 250 mg/m 2 i.v. q 8 h if not tolerated orally. CMV blood antigenemia and shell vial cultures (urine, blood, throat washings) were monitored weekly until day 100 post BMT.
Hemorrhagic cystitis (HC)
HC was defined as two or more episodes of gross (macroscopic) hematuria. HC was graded according to the following criteria: grade 0, no hemorrhagic cystitis; grade I, macroscopic hematuria without clots; grade II, macroscopic hematuria with clots; grade III, macroscopic hematuria with clots and an elevated creatinine secondary to urinary outflow obstruction.
Virus identification: Urine microscopy, a cytospin for urinary sediment morphology, routine culture and sensitivity for bacterial and fungal pathogens and shell vial culture for adenovirus were carried out on all patients developing HC. The A549 lung carcinoma cell line was used to isolate adenovirus. An anti-adenovirus mouse monoclonal antibody detecting all known serotypes of the virus was used to identify virus-infected tissue cultures by an indirect fluorescent antibody staining technique. 9 Serological viral identification was performed on all positive cultures by the State of California Department of Health Services (Berkeley, CA, USA). HC was attributed to polyomavirus infection when characteristic morphologic changes in the urinary sediment were seen in conjunction with urine culture negative for other pathogens.
Treatment of HC:
Supportive care included red cell and platelet transfusions to maintain a hemoglobin above 10 g/dl and a platelet count of 50 000/l. Continuous saline bladder irrigation via a three-way Foley catheter was performed in all patients with grade уII HC until urinary clots resolved. Patients with adenovirus received ribavarin, intravesicularly and/or i.v. Patients with severe intractable HC attributed to polyomavirus were treated with bladder fulguration and intravesicular alum irrigation.
Statistical evaluation
Actuarial probability of developing HC was calculated using the method of Kaplan and Meier. Significant differences between survival of patients who developed HC before day 100 vs those who did not, were calculated using the log rank test.
Results
Hemorrhagic cystitis
Nine of 56 patients developed HC with an actuarial probability of 20% ( Figure 1, Table 1 ). HC occurred in two time periods (Table 2) : six cases occurred between days 15 and 28 and three between days 91 and 362. The median day of onset was day 22. HC was mostly prolonged and severe, lasting from 14 to 92 days (median 21 days) with six of nine developing grade уII HC. All patients required continuous bladder irrigation (CBI) with saline and transfusion support for red cell loss from hematuria. Red cell transfusion requirements varied from 2 to 10 units/week (mean 4.6 units/week).
Etiology of HC
A viral etiology for the HC was confirmed in eight patients. Adenovirus infection occurred in four. Serotyping revealed two infections with adenovirus type 35, one type 5 and one unidentifiable. Four cases of polyomavirus infection were confirmed on urine cytology by the finding of characteristic large, usually uninuclear cells with coarse chromatin, opaque basophilic intranuclear inclusions, and a narrow rim of clearing separating the inclusion from the nuclear envelope. 10 In one patient (UPN47) no causative agent was identified. At autopsy, bladder hemangiomas of unclear etiology were found.
Response of HC to antiviral treatment
There was no clear evidence that any patient with virusrelated HC responded to specific antiviral measures with acyclovir, coincidental ganciclovir or ribavirin. All cases of adenovirus-associated HC occurred before routine use of high-dose acyclovir for CMV/viral, prophylaxis suggesting that these measures may have preventative value for adenovirus HC. Only three patients had resolution of HC and became long-term survivors. Table 1 compares characteristics of patients with and without HC. In a univariate analysis, the only factor associated with the development of HC was a diagnosis of multiple myeloma. Four of 10 (40%) multiple myeloma patients developed HC compared to four of 46 (8.7%) patients with other hematologic malignancies (P = 0.02). There was a trend towards a higher incidence of HC in patients reactivating CMV as compared to those remaining CMV negative (18.4 vs 5.5%, respectively, P = 0.17). HC was not associated with acute GVHD, patient age, sex, or the transplant dose of CD34 + and CD3 + cells. HC occurring before day 100 was significantly associated with a reduction in longterm survival: six of seven (85.6%) patients developing HC before day 100 died, vs 28 of 49 (57.1%) without early HC (P = 0.034) (Figure 2 ). All of these deaths occurred relatively early following the transplant (ie before day 150). In addition, all seven patients with HC who died had active grade уII HC at the time of death.
Risk factors and association of HC with post-transplant mortality
Discussion
These findings indicate that recipients of T cell-depleted allogeneic BMT may be at increased risk for severe viralinduced HC. Previous studies of HC occurring after allogeneic BMT have found the BK polyomavirus to be the predominant causative viral agent. 1, 4, 11 While adenovirus reactivation does occur after BMT, it is a rare pathogen in HC, occurring in 0-5% of patients developing HC following unmanipulated allografts. 4, 12, 13 In contrast, the incidence of adenovirus-induced HC in our population was high (44% of cases). Furthermore, HC is usually caused by adenovirus type 11 or 21 and not types 35 and 5 found in our patients. Type 5 adenovirus found in UPN 14 usually causes respiratory infections and pharyngitis in children and has not previously been reported to cause HC.
14 Type 35 adenovirus in UPN 8 and 22 is an uncommon group B adenovirus found almost exclusively in immunocompromised hosts, particularly HIV-infected patients, but rarely BMT recipients. 15 The occurrence of primary adenovirus type 35 infection following renal transplants suggest the 892 AV = adenovirus; Unk = unidentifiable source; PV = polyomavirus; Tx = transfusional support with PRBCs and platelets; BI = bladder irrigation; F = fulguration; A = alum; R = intravascular ribavirin; HC = hemorrhagic cystitis. No HC before day 100
Days post transplant Probability of survival virus may be latent in the kidneys. 15 It is therefore possible that the defective cellular immunity associated with T celldepleted allogeneic BMT may have been responsible for reactivation of these unusual viral pathogens.
Several studies have shown that polyoma virus BK is excreted in approximately 50% of patients after BMT, with up to 25% developing HC. 1, 4 This viruria is believed to be due to viral reactivation in the uroepithelium. Reactivation of latent polyoma virus BK resulting in viruria accounts for the majority of cases of late HC occurring in recipients of unmanipulated allografts. 4 While the isolation of polyoma virus in our patients was not unusual, the severity and duration of HC encountered was greater than expected. In this study, diagnosis of polyoma virus was limited to identification of characteristic findings on urinary cytology. PCR studies to discriminate between BK and JC virus were not performed.
The 20% incidence of HC seen in our patients is comparable to the 15-50% incidence reported in T cell-replete series. 1, 4, 13 However in our patients HC was prolonged and life-threatening: one of seven patients (14.3%) developing HC before day 100 survived compared with a 42.8% longterm survival in those without HC by day 100. In contrast, HC developing later (after day 100) was more likely to resolve. HC occurred more frequently in patients transplanted for myeloma than other hematologic malignancies (40 vs 11%, respectively, P = 0.02). There was also a trend for HC to occur more frequently in those patients reactivating CMV (21 vs 6% in non-reactivators, P = 0.17). These findings suggest that cellular immune deficiency occurring both prior to BMT (as in the case of myeloma patients) and early after T cell-depleted BMT increased the risk of developing HC. The clustering of onset of HC in the first month after BMT when patients were mostly in protective isolation, together with the association with CMV reactivation, suggested that HC was due to viral reactivation rather than new infection.
Treatment of established HC was disappointing: HC required intensive supportive treatment with red cell and platelet transfusions, bladder irrigation and pain management. There was no benefit from bladder fulguration and no clear response to the antiviral agents ribavirin or gancyclovir. Since treatment of established virally induced HC is unsatisfactory, prevention would appear to be a better strategy. Prophylactic high-dose acyclovir has been reported to delay and reduce CMV reactivation. 8 Interestingly, since the introduction of high-dose acyclovir in our patient series, no additional cases of adenoviral-induced HC or CMV pneumonia have occurred. It is therefore possible that acyclovir had a protective effect against adenovirus (but not polyoma virus) reactivation. Virus-specific cytotoxic T cell clones, able to suppress reactivation of viruses such as CMV, adenovirus and polyomavirus, are indiscriminately removed at the time of T cell depletion, increasing the risk of latent viral reactivation. Although most patients received a delayed add-back of donor T cells, the most severe HC occurred before T cell add-back, preempting any protection from donor lymphocyte transfusion. In the future, it may be possible to reduce the incidence and severity of HC by early administration of viral-specific T cell clones. Drugs with activity against polyoma virus such as adenine arabinoside might provide additional prophylaxis until antiviral T cell immunity is re-established after transplant. 16, 17 
